On (b)(6) 2017, pentax medical (b)(4) was made aware of a report upon receipt of pentax model eg29-i10/serial (b)(4).The report stated non-compliant sampling.Additional information received from the customer indicated the facility reprocessed the device with anioxyde 1000 disinfectant and sampled the device after each reprocessing.In addition, the customer confirmed the device had not been put into service since it was received from pentax medical.Pentax medical received results of the sampling as follows: sampling performed on (b)(6) 2017 indicated 5,6 cfu/100ml of viable bacteria.Sampling performed on (b)(6) 2017 indicated 0,6 cfu/100ml of viable bacteria and 0,6 cfu/100ml of pseudomonas aeruginosa.Sampling performed on (b)(6) 2017 indicated 2,9 cfu/100ml of viable bacteria and 2,1 cfu/100ml of acinetobacter sp.The device was shipped from pentax (b)(4) to pentax (b)(64 for evaluation.
|